lexicon pharmaceuticals - Robuta Search

https://www.benzinga.com/news/earnings/23/05/32131148/earnings-preview-for-lexicon-pharmaceuticals Earnings Preview For Lexicon Pharmaceuticals - Lexicon Pharmaceuticals (NASDAQ:LXRX) - Benzinga lexicon pharmaceuticals earnings preview nasdaq benzinga https://www.ad-hoc-news.de/boerse/news/ueberblick/lexicon-pharmaceuticals-nears-critical-regulatory-milestone/68168718 Lexicon Pharmaceuticals Nears Critical Regulatory Milestone Upcoming FDA Verdict on Diabetes Drug Application lexicon pharmaceuticals nears critical regulatory milestone https://www.fool.com/investing/2020/12/11/why-lexicon-pharmaceuticals-flopped-on-friday/ Why Lexicon Pharmaceuticals Flopped on Friday | The Motley Fool Dec 11, 2020 - More clarification seems warranted for the company's shareholder-diluting move. lexicon pharmaceuticals the motley flopped friday fool https://www.globenewswire.com/news-release/2020/07/30/2070232/0/en/lexicon-pharmaceuticals-enters-into-agreement-with-tersera-therapeutics-for-the-sale-of-xermelo.html Lexicon Pharmaceuticals Enters Into Agreement With TerSera Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer... lexicon pharmaceuticals enters agreement https://www.globenewswire.com/news-release/2026/03/23/3260282/0/en/Lexicon-Pharmaceuticals-and-Novo-Nordisk-Announce-initiation-of-Phase-1-study-with-oral-obesity-drug-candidate-LX9851.html Lexicon Pharmaceuticals and Novo Nordisk Announce LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders ... lexicon pharmaceuticals novo nordisk announce https://www.globenewswire.com/de/news-release/2020/07/30/2070232/0/en/lexicon-pharmaceuticals-enters-into-agreement-with-tersera-therapeutics-for-the-sale-of-xermelo.html Lexicon Pharmaceuticals Enters Into Agreement With TerSera Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer... lexicon pharmaceuticals enters agreement https://www.macrotrends.net/stocks/charts/LXRX/lexicon-pharmaceuticals/long-term-debt Lexicon Pharmaceuticals Long Term Debt 2012-2026 | LXRX | MacroTrends Lexicon Pharmaceuticals long term debt from 2012 to 2026. Long term debt can be defined as the sum of all long term debt fields. lexicon pharmaceuticals long term debt 2012 2026 https://www.financialcontent.com/article/gnwcq-2026-5-7-lexicon-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-clinical-updates Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates... SONATA-HCM anticipated to be fully enrolled mid-2026 first quarter 2026 lexicon pharmaceuticals https://www.globenewswire.com/fr/news-release/2020/07/30/2070232/0/en/lexicon-pharmaceuticals-enters-into-agreement-with-tersera-therapeutics-for-the-sale-of-xermelo.html Lexicon Pharmaceuticals Enters Into Agreement With TerSera Lexicon to Receive Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer... lexicon pharmaceuticals enters agreement https://www.biospace.com/lexicon-pharmaceuticals-inc-announces-completion-of-public-offering-of-common-stock Lexicon Pharmaceuticals, Inc. Announces Completion of Public Offering of Common Stock - BioSpace lexicon pharmaceuticals public offering common stock inc announces https://www.fool.com/investing/general/2015/09/10/heres-why-lexicon-pharmaceuticals-exploded-higher.aspx Here's Why Lexicon Pharmaceuticals' Stock Exploded Higher in August | The Motley Fool Sep 10, 2015 - Lexicon Pharmaceuticals' long-awaited success in a pivotal late-stage trial sent shares soaring in August.